- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07944157
Construction and Validation of a Clinical Cohort on the Pathogenesis Evolution and Syndrome-Differentiated Treatment of Chronic Obstructive Pulmonary Disease Based on Core Targets of Airway Inflammation and Remodeling
This multicenter, randomized, open-label clinical trial will enroll 360 adults with chronic obstructive pulmonary disease (COPD): 240 with stable COPD and 120 hospitalized with an acute exacerbation (AECOPD). Participants will be stratified by disease stage and traditional Chinese medicine (TCM) syndrome. Within each syndrome stratum, they will be assigned to standardized Western medical treatment alone or the same treatment plus a syndrome-specific optimized herbal formula; selected strata will also include an innovative herbal formula group. Stable-phase participants will receive the study herbal treatment for 12 weeks, and AECOPD participants for 2 weeks. Both cohorts will be followed for 24 weeks. The study will assess lung function and exacerbations in stable COPD, and early dyspnea improvement and length of hospital stay in AECOPD. It will also assess symptoms, quality of life, TCM syndrome scores, safety, and biological markers.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: Yuping Yifei herbal formula
- Médicament: standardized Western medical treatment
- Médicament: Liujun Fuzheng herbal formula
- Médicament: Qiyi Peitu herbal formula
- Médicament: Shenqi Naqi herbal formula
- Médicament: Fufei Gushen herbal formula
- Médicament: Shengmai Runyuan herbal formula
- Médicament: Qinbei Qingfei herbal formula
- Médicament: Erchen Shunqi herbal formula
- Médicament: Banlou Kuanxiong herbal formula
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: chao cao
- Numéro de téléphone: +8618258796166
- E-mail: caocdoctor@163.com
Lieux d'étude
-
-
Guangdong
-
Dongguan, Guangdong, Chine
- Dongguan People's Hospital
-
Contact:
- Zhengzheng Yan
- Numéro de téléphone: +86 13249194561
- E-mail: yzzaici888@163.com
-
Guangzhou, Guangdong, Chine
- The First Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Yuqiong Yang
- Numéro de téléphone: +86 15622136450
- E-mail: yangyuqiongcoma@163.com
-
-
Henan
-
Zhengzhou, Henan, Chine
- The First Affiliated Hospital of Henan University of Chinese Medicine
-
Contact:
- Zhenzhen Feng
- Numéro de téléphone: +86 15890658268
- E-mail: Huxifzz@163.com
-
-
Zhejiang
-
Ningbo, Zhejiang, Chine, 315000
- The First Affiliated Hospital of Ningbo University
-
Contact:
- Chao Cao
- Numéro de téléphone: +86 18258796166
- E-mail: caocdoctor@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria - Stable COPD cohort:
- COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70.
- Age 40 years or older, any sex.
- Clinically stable during the 4 weeks before enrollment, without a COPD exacerbation or initiation/change of systemic antibiotics or systemic glucocorticoids for worsening respiratory symptoms.
- Predominant TCM syndrome of lung qi deficiency, lung-spleen qi deficiency, lung-kidney qi deficiency, or lung-kidney qi-yin deficiency, according to the 2011 TCM syndrome diagnostic criteria for COPD.
- Able to understand the study and provide written informed consent.
- Able to complete clinical assessments, sample collection, and follow-up.
Exclusion Criteria - Stable COPD cohort:
- Systemic antibiotics or systemic glucocorticoids within 2 weeks before enrollment, or long-term systemic glucocorticoid maintenance therapy.
- TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
- Active pulmonary tuberculosis, pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
- Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
- Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
- Allergy to study herbal components or a contraindication to herbal therapy.
- Pregnancy, breastfeeding, or planned pregnancy.
- Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
- Investigator judges participation unsuitable.
Inclusion Criteria - Hospitalized AECOPD cohort:
- COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70; current acute exacerbation assessed clinically.
- Age 40 years or older, any sex.
- Hospitalized for the current AECOPD episode, with screening and randomization completed within 24 hours after admission.
- Onset of acute worsening of respiratory symptoms no more than 5 days before enrollment.
- Cumulative systemic antibiotic and/or systemic glucocorticoid treatment for the current episode no more than 48 hours before enrollment.
- Predominant TCM syndrome of phlegm-heat obstructing the lung or phlegm-turbidity obstructing the lung, according to the 2011 TCM syndrome diagnostic criteria for COPD.
- Able to understand the study and provide written informed consent.
- Able to complete clinical assessments, sample collection, and follow-up.
Exclusion Criteria - Hospitalized AECOPD cohort:
- Deterioration not attributable to AECOPD; active pulmonary tuberculosis, invasive fungal disease, or pulmonary infection requiring pathogen-specific treatment as judged by the investigator.
- Pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
- Systemic antibiotics or systemic glucocorticoids for reasons other than the current exacerbation within 2 weeks, or long-term systemic glucocorticoid maintenance therapy.
- TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
- Immediate need for intensive care, invasive mechanical ventilation, altered consciousness, or hemodynamic instability at enrollment.
- Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
- Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
- Allergy to study herbal components or a contraindication to herbal therapy.
- Pregnancy, breastfeeding, or planned pregnancy.
- Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
- Investigator judges participation unsuitable.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Stable COPD - Lung Qi Deficiency - Optimized Yuping Yifei Formula
24 participants with stable COPD and lung qi deficiency receive the optimized Yuping Yifei herbal formula plus standardized Western medical treatment for 12 weeks. |
Stable COPD, lung qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fangfeng 6 g, Wuweizi 6 g, Ziwan 9 g, and Sangbaipi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment. Administer standardized Western medical treatment in accordance with the GOLD guidelines |
|
Comparateur actif: Stable COPD - Lung Qi Deficiency - Standard Western Treatment
24 participants with stable COPD and lung qi deficiency receive standardized Western medical treatment without the study herbal formula. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines |
|
Expérimental: Stable COPD - Lung-Spleen Qi Deficiency - Optimized Liujun Fuzheng Formula
24 participants with stable COPD and lung-spleen qi deficiency receive the optimized Liujun Fuzheng herbal formula plus standardized Western medical treatment for 12 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 12 g, Chenpi 9 g, ginger-processed Banxia 9 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment. |
|
Expérimental: Stable COPD - Lung-Spleen Qi Deficiency - Innovative Qiyi Peitu Formula
24 participants with stable COPD and lung-spleen qi deficiency receive the innovative Qiyi Peitu herbal formula plus standardized Western medical treatment for 12 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 15 g, Shanyao 20 g, Yiyiren 20 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment. |
|
Comparateur actif: Stable COPD - Lung-Spleen Qi Deficiency - Standard Western Treatment
24 participants with stable COPD and lung-spleen qi deficiency receive standardized Western medical treatment without the study herbal formula. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines |
|
Expérimental: Stable COPD - Lung-Kidney Qi Deficiency - Optimized Shenqi Naqi Formula
24 participants with stable COPD and lung-kidney qi deficiency receive the optimized Shenqi Naqi herbal formula plus standardized Western medical treatment for 12 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Stable COPD, lung-kidney qi deficiency: Dangshen 20 g, Huangqi 30 g, salt-processed Duzhong 12 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Fuling 12 g, and ginger-processed Banxia 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment. |
|
Expérimental: Stable COPD - Lung-Kidney Qi Deficiency - Innovative Fufei Gushen Formula
24 participants with stable COPD and lung-kidney qi deficiency receive the innovative Fufei Gushen herbal formula plus standardized Western medical treatment for 12 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Stable COPD, lung-kidney qi deficiency: Huangqi 30 g, Renshen 6 g, Yinyanghuo 9 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Gouqizi 15 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment. |
|
Comparateur actif: Stable COPD - Lung-Kidney Qi Deficiency - Standard Western Treatment
24 participants with stable COPD and lung-kidney qi deficiency receive standardized Western medical treatment without the study herbal formula. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines |
|
Expérimental: Stable COPD - Lung-Kidney Qi-Yin Deficiency - Optimized Shengmai Runyuan Formula
24 participants with stable COPD and lung-kidney qi-yin deficiency receive the optimized Shengmai Runyuan herbal formula plus standardized Western medical treatment for 12 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Stable COPD, lung-kidney qi-yin deficiency: Dangshen 15 g, Zhemaidong 10 g, Wuweizi 6 g, Shudihuang 15 g, Shanzhuyu 12 g, Shanyao 20 g, Huangqi 30 g, and Danshen 15 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment. |
|
Comparateur actif: Stable COPD - Lung-Kidney Qi-Yin Deficiency - Standard Western Treatment
24 participants with stable COPD and lung-kidney qi-yin deficiency receive standardized Western medical treatment without the study herbal formula. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines |
|
Expérimental: AECOPD - Phlegm-Heat Obstructing Lung - Optimized Qinbei Qingfei Formula
24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive the optimized Qinbei Qingfei herbal formula plus standardized Western medical treatment for 2 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Hospitalized AECOPD, phlegm-heat obstructing the lung: Huangqin 9 g, Zhebeimu 10 g, Sangbaipi 12 g, Yuxingcao 20 g, Qingbanxia 9 g, Zisuzi 9 g, and honey-processed Mahuang 5 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment. |
|
Comparateur actif: AECOPD - Phlegm-Heat Obstructing Lung - Standard Western Treatment
24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive standardized Western medical treatment without the study herbal formula. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines |
|
Expérimental: AECOPD - Phlegm-Turbidity Obstructing Lung - Optimized Erchen Shunqi Formula
24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the optimized Erchen Shunqi herbal formula plus standardized Western medical treatment for 2 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Zisuzi 9 g, Baijiezi 6 g, and Laifuzi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment. |
|
Expérimental: AECOPD - Phlegm-Turbidity Obstructing Lung - Innovative Banlou Kuanxiong Formula
24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the innovative Banlou Kuanxiong herbal formula plus standardized Western medical treatment for 2 weeks. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Gualoupi 9 g, Gualouren 6 g, Kuxingren 9 g, and Jiegeng 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment. |
|
Comparateur actif: AECOPD - Phlegm-Turbidity Obstructing Lung - Standard Western Treatment
24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive standardized Western medical treatment without the study herbal formula. |
Administer standardized Western medical treatment in accordance with the GOLD guidelines |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in FEV1 Percent Predicted at Week 24 (Stable COPD)
Délai: Baseline (T0) and Week 24
|
Absolute change from baseline in post-bronchodilator forced expiratory volume in one second as a percentage of the predicted value (FEV1%pred). |
Baseline (T0) and Week 24
|
|
Time to First Hospitalized COPD Exacerbation Through Week 24 (Stable COPD)
Délai: From baseline (T0) through Week 24
|
Time from T0 to the first acute COPD exacerbation requiring hospitalization. Exacerbations managed without hospitalization are not counted for this outcome. |
From baseline (T0) through Week 24
|
|
Number of Hospitalized COPD Exacerbations Through Week 24 (Stable COPD)
Délai: From baseline (T0) through Week 24
|
Count of acute COPD exacerbations requiring hospitalization from T0 through Week 24. Episodes treated only in outpatient or emergency settings without admission are not counted. |
From baseline (T0) through Week 24
|
|
Change in Dyspnea Numeric Rating Scale Score on Day 4 (AECOPD)
Délai: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
|
Absolute change from baseline in the average dyspnea numeric rating scale (NRS) score over the preceding 24 hours. |
Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
|
|
Proportion With at Least a 1-Point Improvement in Dyspnea NRS on Day 4 (AECOPD)
Délai: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
|
Proportion of participants whose average dyspnea NRS score over the preceding 24 hours decreases by at least 1 point from baseline. |
Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
|
|
Total Length of Hospital Stay for the Index AECOPD Admission
Délai: From hospital admission to discharge for the index AECOPD episode
|
Number of days from admission for the index acute exacerbation to hospital discharge. |
From hospital admission to discharge for the index AECOPD episode
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in COPD Assessment Test (CAT) Score
Délai: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
|
Change from baseline in CAT total score in the stable COPD and AECOPD cohorts. |
Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
|
|
Change in TCM Syndrome Efficacy Score
Délai: Baseline and scheduled assessments through Week 24
|
Change from baseline in the syndrome-specific TCM symptom score using the appropriate stable-phase or AECOPD assessment scale. |
Baseline and scheduled assessments through Week 24
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) Score
Délai: Baseline, Week 12, and Week 24
|
Change from baseline in SGRQ total score. |
Baseline, Week 12, and Week 24
|
|
Change in Modified Medical Research Council (mMRC) Dyspnea Grade
Délai: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
|
Change from baseline in the mMRC dyspnea grade, an ordinal measure of breathlessness, in stable COPD and hospitalized AECOPD participants. |
Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
|
|
Change in Airway Wall Area Percentage on HRCT
Délai: Baseline and Week 24
|
Absolute change from baseline in airway wall area percentage (WA%) derived from quantitative high-resolution computed tomography. |
Baseline and Week 24
|
|
Change in Emphysema Index on HRCT
Délai: Baseline and Week 24
|
Absolute change from baseline in emphysema index derived from quantitative high-resolution computed tomography. |
Baseline and Week 24
|
|
Change in Airway Wall Thickness on HRCT
Délai: Baseline and Week 24
|
Absolute change from baseline in airway wall thickness derived from quantitative high-resolution computed tomography. |
Baseline and Week 24
|
|
Change in C-Reactive Protein Concentration
Délai: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
Absolute change from baseline in peripheral-blood C-reactive protein concentration as an inflammation marker. |
Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
|
Change in Interleukin-6 Concentration
Délai: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
Absolute change from baseline in interleukin-6 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable. |
Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
|
Change in Interleukin-8 Concentration
Délai: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
Absolute change from baseline in interleukin-8 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable. |
Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
|
Change in Tumor Necrosis Factor Alpha Concentration
Délai: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
Absolute change from baseline in tumor necrosis factor alpha concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable. |
Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
|
|
Change in FEV1 Percent Predicted After AECOPD
Délai: Baseline when feasible, Weeks 12 and 24
|
Absolute change from baseline in post-bronchodilator FEV1 percent predicted among hospitalized AECOPD participants able to undergo safe and valid spirometry. |
Baseline when feasible, Weeks 12 and 24
|
|
Incidence of Adverse Events
Délai: From baseline through Week 24
|
Number and proportion of participants experiencing at least one adverse event during treatment and follow-up, with event type, severity, and relationship to study herbal treatment recorded. |
From baseline through Week 24
|
|
Incidence of Serious Adverse Events
Délai: From baseline through Week 24
|
Number and proportion of participants experiencing at least one serious adverse event during treatment and follow-up, with severity, management, outcome, and relationship to study herbal treatment recorded. |
From baseline through Week 24
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026-R058-02
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data underlying the results reported in the main publication, including baseline characteristics, treatment allocation, and outcome data, will be available upon reasonable request. Direct personal identifiers will not be shared.
Délai de partage IPD
Beginning after publication of the main study results, subject to applicable institutional and ethics requirements.
Critères d'accès au partage IPD
Qualified researchers may request access by submitting a research proposal to the study contact, together with ethics approval where applicable. Requests will be reviewed by the study team and relevant institutional or ethics bodies. Approved researchers will receive de-identified data under a data-use agreement. Re-identification and onward sharing are prohibited.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .